Zydus Lifesciences gets FDA approval for Phase 2b ALS trial of Usnoflast
Zydus Lifesciences, a global leader in pharmaceutical innovation, has received approval from the United States Food and Drug Administration (USFDA) to commence Phase II(b) clinical ... Read More
Athira Pharma stock nosedives after Alzheimer’s drug trial results disappoint
Athira Pharma's stock plunged by 75% after the company announced that its Phase 2/3 LIFT-AD clinical trial for its experimental Alzheimer’s drug, fosgonimeton, failed to ... Read More
Amylyx Pharmaceuticals’ AMX0035 misses primary and secondary endpoints in ALS study
Cambridge, Massachusetts-based Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a key player in the pharmaceutical industry, announced today the top-line results of the PHOENIX study, a critical ... Read More
Nura Bio kicks off Phase 1 clinical trials for SARM1 inhibitor NB-4746
Nura Bio, a leading biopharmaceutical company specializing in neuroprotective, small molecule therapies, announced today the initiation of Phase 1 clinical trials for its groundbreaking SARM1 ... Read More
Amylyx Pharmaceuticals gets RELYVRIO FDA approval for ALS
RELYVRIO FDA approval for ALS : Amylyx Pharmaceuticals has secured approval for RELYVRIO (sodium phenylbutyrate and taurursodiol) from the US Food and Drug Administration (FDA) ... Read More
BrainStorm Cell Therapeutics doses patients in NurOwn phase 3 trial in ALS
NurOwn phase 3 trial : BrainStorm Cell Therapeutics, a US biotech company engaged in developing adult stem cell therapies for neurodegenerative diseases, has completed the ... Read More
Yumanity secures $500m worth deal with Merck to develop therapies for neurodegenerative disorders
Massachusetts-based Yumanity Therapeutics has secured a drug development deal worth up to nearly $500 million with pharma giant Merck to develop new therapies for neurodegenerative ... Read More
Alexion discloses plan for CHAMPION-ALS clinical trial of ULTOMIRIS
Alexion Pharmaceuticals has revealed plans for initiating the CHAMPION-ALS clinical trial, a phase 3 study to evaluate ULTOMIRIS (ravulizumab) for the treatment of amyotrophic lateral ... Read More
CMD enrolls first patient in placebo-controlled ALS trial of CuATSM
Collaborative Medicinal Development (CMD) has enrolled the first patient in a placebo-controlled clinical trial to evaluate the safety and efficacy of CuATSM in patients with ... Read More